Studies biomarkers of progression in relapsing multiple sclerosis after transplant or second-line treatment
Observes whether strong treatments slow multiple sclerosis by changing immune cells in adults.
Plain-language title generated from the registry record
Registry title: RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- IRCCS San RaffaeleMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS San Raffaele
- Trial code
- NCT06267781
- Record updated
- 20 February 2024
- Original description
To study whether highly effective therapies can halt disease progression in people with multiple sclerosis by modulating the peripheral myeloid landscape.Read full original descriptionShow less
Biomarkers of Disease PROgression and Myeloid Profiling in Patients With Relapsing Remitting Multiple Sclerosis Treated With Autologous Hematopoietic Stem Cell TRANSPLANTation and Second Line Therapies.
To study whether highly effective therapies can halt disease progression in people with multiple sclerosis by modulating the peripheral myeloid landscape.
Inclusion: Age ≥18 years; Signed written informed consent; A diagnosis of RRMS according to the 2017 Revisions of the McDonald Criteria; High clinical and magnetic resonance imaging (MRI) inflammatory disease activity (at least 2 clinical relapses, or one clinical relapse with gadolinium (Gd)- enhancing or new T2 MRI lesions at a separate time point, in the previous 12 months); Patients referred for pharmacological treatment with aHSCT, alemtuzumab or ocrelizumab /ofatumumab, according to clinical practice following the Italian pharmacological regulatory agency (AIFA) criteria and guidelines and recommendations from the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE).
Exclusion: Known intolerances/allergies to the active substance or the excipients contained in the DMT and/or contraindications according to product information; Diagnosis of PPMS or SPMS according to the 2017 McDonald criteria.